Switch theme
Sign up to access all valuation multiples
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
2017
35
LTM Revenue $24.1M
Last FY EBITDA -$7.6M
-$1.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Equillium has a last 12-month revenue (LTM) of $24.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Equillium achieved revenue of $41.1M and an EBITDA of -$7.6M.
Equillium expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Equillium valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $24.1M | XXX | $41.1M | XXX | XXX | XXX |
| Gross Profit | $24.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$7.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -18% | XXX | XXX | XXX |
| EBIT | -$18.7M | XXX | -$8.3M | XXX | XXX | XXX |
| EBIT Margin | -77% | XXX | -20% | XXX | XXX | XXX |
| Net Profit | -$18.9M | XXX | -$8.1M | XXX | XXX | XXX |
| Net Margin | -79% | XXX | -20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Equillium's stock price is $0.
Equillium has current market cap of $13.2M, and EV of -$1.0M.
See Equillium trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.0M | $13.2M | XXX | XXX | XXX | XXX | $-0.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Equillium has market cap of $13.2M and EV of -$1.0M.
Equillium's trades at -0.0x EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Equillium's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Equillium has a P/E ratio of -0.7x.
See valuation multiples for Equillium and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.2M | XXX | $13.2M | XXX | XXX | XXX |
| EV (current) | -$1.0M | XXX | -$1.0M | XXX | XXX | XXX |
| EV/Revenue | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -0.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEquillium's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $1.4M for the same period.
Equillium's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Equillium's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Equillium and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -18% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 91% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 120% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Equillium acquired XXX companies to date.
Last acquisition by Equillium was XXXXXXXX, XXXXX XXXXX XXXXXX . Equillium acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Equillium founded? | Equillium was founded in 2017. |
| Where is Equillium headquartered? | Equillium is headquartered in United States of America. |
| How many employees does Equillium have? | As of today, Equillium has 35 employees. |
| Who is the CEO of Equillium? | Equillium's CEO is Mr. Bruce D. Steel. |
| Is Equillium publicy listed? | Yes, Equillium is a public company listed on NAS. |
| What is the stock symbol of Equillium? | Equillium trades under EQ ticker. |
| When did Equillium go public? | Equillium went public in 2018. |
| Who are competitors of Equillium? | Similar companies to Equillium include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Equillium? | Equillium's current market cap is $13.2M |
| What is the current revenue of Equillium? | Equillium's last 12 months revenue is $24.1M. |
| What is the current EV/Revenue multiple of Equillium? | Current revenue multiple of Equillium is -0.0x. |
| Is Equillium profitable? | Yes, Equillium is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
